Exicure (Exicure) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 15, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Exicure EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Exicure (NAS:XCUR) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Exicure EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Exicure's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Exicure (Exicure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

2H0A:Germany 2H0A:Germany

Address

2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614

Website

https://www.exicuretx.com

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Executives

Minhee Eom	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd.	10 percent owner	23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim	director, officer: Chief Executive Officer, CFO	46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller	director, officer: Chief Executive Officer, CFO	2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang	director	C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo	director	2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul	director	2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn	director	2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc.	10 percent owner	3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077